Last reviewed · How we verify
NCT03066661
Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
trial testing Entrectinib in Cancers With NTRK, ROS1, or ALK Gene Fusions. No longer available.
Quick facts
| Lead sponsor | Hoffmann-La Roche |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- Entrectinib (entrectinib) — full drug profile →
Conditions studied
- Cancers With NTRK, ROS1, or ALK Gene Fusions — all drugs for Cancers With NTRK, ROS1, or ALK Gene Fusions →
Sponsor
Hoffmann-La Roche — full company profile →
Who can join
Eligibility, any sex, with Cancers With NTRK, ROS1, or ALK Gene Fusions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.
Schram AM, Chang MT, Jonsson P, Drilon A. · · 2017 · cited 270× · PMID 28857077 · DOI 10.1038/nrclinonc.2017.127 -
Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors.
Lake JA, Donson AM, Prince E, Davies KD, et al · · 2020 · cited 49× · PMID 31595628 · DOI 10.1002/pbc.28028 -
BDNF and its signaling in cancer.
Malekan M, Nezamabadi SS, Samami E, Mohebalizadeh M, et al · · 2023 · cited 48× · PMID 36173463 · DOI 10.1007/s00432-022-04365-8 -
Clinically relevant fusion oncogenes: detection and practical implications.
Sorokin M, Rabushko E, Rozenberg JM, Mohammad T, et al · · 2022 · cited 25× · PMID 36601633 · DOI 10.1177/17588359221144108 -
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020.
Kooijman JJ, van Riel WE, Dylus J, Prinsen MBW, et al · · 2022 · cited 16× · PMID 36185300 · DOI 10.3389/fonc.2022.953013 -
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?
Tran TH, Tasian SK. · · 2021 · cited 11× · PMID 34865703 · DOI 10.1016/j.beha.2021.101331 -
Insights in Molecular Therapies for Hepatocellular Carcinoma.
Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 5× · PMID 38791911 · DOI 10.3390/cancers16101831 -
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.
Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 4× · PMID 38730642 · DOI 10.3390/cancers16091690
Verify or expand the search:
- PubMed search for NCT03066661
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Entrectinib
Trials testing the same drug.
- NCT07199959 — Study on the Mechanism of Acquired Resistance of Entrectinib · recruiting
- NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
- NCT06694129 — Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC · not yet recruiting
- NCT05862285 — A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study · Phase 3 · recruiting
- NCT05238831 — SMMART Adaptive Clinical Treatment (ACT) Trial · EARLY_PHASE1 · withdrawn
Other Hoffmann-La Roche trials
Trials by the same sponsor.
- NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
- NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
- NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
- NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
- NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03066661 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
- Last refreshed: 26 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03066661.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing